Organogenesis (NASDAQ:ORGO) specializes in regenerative medicine, focusing on the development, manufacturing, and commercialization of solutions for the advanced wound care, surgical, and sports medicine markets. Its portfolio encompasses a wide range of products designed to facilitate the body's own healing process. The company is dedicated to improving patient outcomes and reducing healthcare costs through its innovative therapies. With a strong commitment to research and development, Organogenesis aims to expand its product offerings and explore new applications for its regenerative medicine technologies. By continuously advancing the field of regenerative medicine, Organogenesis seeks to address unmet medical needs and enhance the quality of life for patients around the world.